{"hands_on_practices": [{"introduction": "The correct diagnosis of cervical insufficiency is a cornerstone of appropriate management, demanding the crucial differentiation from its mimics like preterm labor or intra-amniotic infection. This exercise guides you through the process of synthesizing real-time clinical data—maternal temperature, inflammatory markers, and uterine activity—to formulate a safe and effective decision algorithm. Mastering this skill [@problem_id:4411079] is essential because placing a cerclage in the presence of infection or active labor can lead to severe adverse outcomes.", "problem": "A pregnant patient at $22$ weeks presents with painless cervical dilation to $3$ cm and visible membranes at the external os on speculum examination. The bedside tocometer is available, laboratory testing can provide a same-day C-reactive protein (CRP) result, and rapid vaginal Gram stain with culture setup will be performed (final culture results in $48$ to $72$ hours). Emergent cerclage is being considered.\n\nFrom first principles in obstetrics and gynecology, cervical insufficiency is defined by painless cervical dilation in the second trimester in the absence of labor or intrauterine infection. In contrast, infection-driven dilation reflects intrauterine inflammation or ascending infection that can precipitate contractions or cause cervical changes, where cerclage increases the risk of maternal and fetal harm. Uterine activity monitoring (tocometer) quantifies contractile patterns; sustained regular contractions indicate preterm labor. Maternal fever reflects systemic inflammatory response; C-reactive protein (CRP) is an acute-phase reactant associated with inflammation but lacks perfect specificity. Vaginal culture reflects lower genital tract flora and may not equal intra-amniotic infection at the time of presentation; however, a positive culture with concurrent systemic markers of inflammation increases the probability of infection-driven cervical change.\n\nSelect the most appropriate decision algorithm that separates true cervical insufficiency from infection-driven dilation by integrating maternal temperature, CRP, vaginal culture, and uterine activity monitoring, and that provides a scientifically sound, time-sensitive basis for proceeding with or deferring emergent cerclage.\n\nA. Classify as cervical insufficiency and proceed with emergent cerclage only if all of the following are present at presentation: maternal temperature $38.0\\,^{\\circ}\\mathrm{C}$, CRP $20\\,\\mathrm{mg/L}$, and no regular uterine activity on tocometer (e.g., fewer than $4$ contractions in $20$ minutes). If any of the following are present—maternal temperature $\\geq 38.0\\,^{\\circ}\\mathrm{C}$, CRP $\\geq 20\\,\\mathrm{mg/L}$, or regular contractions—classify as infection- or labor-associated dilation and defer cerclage, initiate antibiotics if infection is suspected, and manage preterm labor as indicated. Do not delay cerclage solely for final vaginal culture results; if the culture later grows a pathogenic organism and the patient develops clinical signs of infection, remove cerclage and treat infection.\n\nB. Proceed with emergent cerclage in all patients with painless dilation unless the initial vaginal culture is positive; if the culture is positive, defer cerclage. Uterine activity and CRP should not influence the decision because contractions can be suppressed with tocolysis and CRP is nonspecific.\n\nC. Require a negative vaginal culture before cerclage to exclude infection. While awaiting the final culture result over $48$ to $72$ hours, observe the patient; if the cervix dilates further, start tocolysis and proceed with cerclage even if maternal temperature is $\\geq 38.0\\,^{\\circ}\\mathrm{C}$ and CRP is elevated, because the benefits of mechanical support outweigh the risks.\n\nD. Use a low-threshold inflammatory trigger: if either maternal temperature $\\geq 37.5\\,^{\\circ}\\mathrm{C}$ or CRP $\\geq 5\\,\\mathrm{mg/L}$, classify as infection-driven dilation and defer cerclage; if both are below these thresholds, proceed with cerclage regardless of the presence of regular uterine contractions, because contractions in the second trimester are often physiological and do not contraindicate cerclage.", "solution": "The user has requested a meticulous validation of the problem statement, followed by a solution derived from first principles.\n\n**Problem Validation**\n\n**Step 1: Extract Givens**\n-   Patient status: pregnant at $22$ weeks.\n-   Clinical presentation: painless cervical dilation to $3$ cm, visible membranes at the external os.\n-   Available diagnostic tools: bedside tocometer, same-day C-reactive protein (CRP) result, rapid vaginal Gram stain with culture setup.\n-   Time for final culture results: $48$ to $72$ hours.\n-   Procedure under consideration: Emergent cerclage.\n-   Definition of cervical insufficiency: painless cervical dilation in the second trimester in the absence of labor or intrauterine infection.\n-   Definition of infection-driven dilation: reflects intrauterine inflammation or ascending infection, can precipitate contractions or cause cervical changes.\n-   Contraindication for cerclage: placing a cerclage in the presence of infection-driven dilation increases risk of maternal and fetal harm.\n-   Uterine activity monitoring (tocometer): quantifies contractile patterns; sustained regular contractions indicate preterm labor.\n-   Maternal fever: reflects systemic inflammatory response.\n-   C-reactive protein (CRP): an acute-phase reactant associated with inflammation; lacks perfect specificity.\n-   Vaginal culture: reflects lower genital tract flora, may not equal intra-amniotic infection.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem statement is evaluated against the established criteria.\n\n-   **Scientifically Grounded:** The problem is firmly rooted in the established principles of obstetrics and gynecology. The clinical scenario of second-trimester painless cervical dilation is a classic presentation that requires differentiation between true cervical insufficiency and mimics like preterm labor or intra-amniotic infection. The definitions provided, the diagnostic tools mentioned (tocometry, CRP, culture), and the risks associated with cerclage in the setting of infection are all consistent with current medical knowledge and clinical practice guidelines. For instance, the use of tocometry to detect uterine contractions, maternal temperature to screen for infection, and CRP as an inflammatory marker are standard procedures. The contraindication of cerclage for active labor or suspected chorioamnionitis is a cornerstone of safe obstetric practice. The problem is scientifically sound.\n-   **Well-Posed:** The problem is well-posed. It presents a clear clinical dilemma with a defined set of patient data and available diagnostic tests. The goal is to select the most appropriate decision-making algorithm from a given set of choices. A unique and meaningful evaluation of the options is possible based on the provided principles.\n-   **Objective:** The language is clinical, precise, and objective. It defines its terms (e.g., cervical insufficiency) and avoids subjective or opinion-based assertions in the problem setup.\n\nThe problem statement has no identifiable flaws. It does not violate scientific principles, is not incomplete or contradictory, is clinically realistic, and is well-structured.\n\n**Step 3: Verdict and Action**\nThe problem is valid. We may proceed to the solution.\n\n**Derivation of Solution from First Principles**\n\nThe central challenge is to reliably and rapidly distinguish true cervical insufficiency from its two primary mimics: preterm labor and intra-amniotic infection. The decision to place an emergent cerclage is time-sensitive, as progressive cervical dilation or rupture of membranes will preclude the procedure. However, placing a cerclage in the setting of active labor or infection is strongly contraindicated due to high risks of cervical trauma, uterine rupture, and fulminant maternal/fetal infection (chorioamnionitis and sepsis).\n\nAn optimal decision algorithm must prioritize safety by effectively ruling out labor and infection using the most reliable and rapid tests available.\n\n1.  **Assessment for Preterm Labor:** The defining feature of preterm labor is the presence of regular uterine contractions that cause cervical change. The tocometer is the direct tool for this assessment. The presence of sustained, regular uterine activity is an absolute contraindication to cerclage. The procedure is intended for a weak cervix, not to hold back the force of an actively contracting uterus.\n\n2.  **Assessment for Infection/Inflammation:** Intra-amniotic infection is a critical contraindication. Clinical signs and laboratory markers must be used for screening.\n    -   **Maternal Temperature:** Fever (clinically defined as a core temperature $\\geq 38.0\\,^{\\circ}\\mathrm{C}$ or $100.4\\,^{\\circ}\\mathrm{F}$) is a cardinal sign of infection, such as chorioamnionitis. Its presence is a strong contraindication to cerclage.\n    -   **C-Reactive Protein (CRP):** CRP is a sensitive, but non-specific, acute-phase reactant. In this context, its value lies in its rapid availability and its utility as a marker for subclinical inflammation. While a mild elevation can have many causes, a significant elevation greatly increases the suspicion of an underlying inflammatory process like intra-amniotic infection, even in an afebrile patient. A low CRP is reassuring, though it does not completely exclude infection. Therefore, a reasonable upper threshold for CRP should be incorporated into the decision algorithm.\n    -   **Vaginal Culture:** The results take $48$ to $72$ hours, which is too long to wait in an emergent situation. The cervix may fully dilate or membranes may rupture during this waiting period, making cerclage impossible. Furthermore, vaginal flora do not perfectly correlate with intra-amniotic status. Therefore, the decision to proceed with cerclage cannot be contingent on awaiting final culture results.\n\nSynthesizing these principles, the most scientifically sound and safest algorithm is one that proceeds with emergent cerclage **only if** there is no evidence of active labor (no regular contractions), no overt sign of systemic infection (no fever), and no significant laboratory evidence of inflammation (CRP below a clinically reasonable threshold). If any of these \"red flags\" are present, the risk of harm outweighs the potential benefit of cerclage, and the procedure should be deferred in favor of managing suspected labor or infection.\n\n**Evaluation of Options**\n\n**A. Classify as cervical insufficiency and proceed with emergent cerclage only if all of the following are present at presentation: maternal temperature $38.0\\,^{\\circ}\\mathrm{C}$, CRP $20\\,\\mathrm{mg/L}$, and no regular uterine activity on tocometer (e.g., fewer than $4$ contractions in $20$ minutes). If any of the following are present—maternal temperature $\\geq 38.0\\,^{\\circ}\\mathrm{C}$, CRP $\\geq 20\\,\\mathrm{mg/L}$, or regular contractions—classify as infection- or labor-associated dilation and defer cerclage, initiate antibiotics if infection is suspected, and manage preterm labor as indicated. Do not delay cerclage solely for final vaginal culture results; if the culture later grows a pathogenic organism and the patient develops clinical signs of infection, remove cerclage and treat infection.**\n\nThis option aligns perfectly with the principles derived above.\n-   It correctly uses the absence of regular uterine contractions as a criterion.\n-   It uses the standard temperature threshold for fever ($\\geq 38.0\\,^{\\circ}\\mathrm{C}$) as a contraindication.\n-   It incorporates a rapid inflammatory marker (CRP) with a reasonable threshold ($20\\,\\mathrm{mg/L}$) to screen for subclinical infection. The logical structure (\"AND\") ensures all three safety checks must be passed.\n-   It correctly prioritizes a timely decision by not waiting for culture results.\n-   The contingency plan for a later positive culture is clinically appropriate.\n**Verdict: Correct.**\n\n**B. Proceed with emergent cerclage in all patients with painless dilation unless the initial vaginal culture is positive; if the culture is positive, defer cerclage. Uterine activity and CRP should not influence the decision because contractions can be suppressed with tocolysis and CRP is nonspecific.**\n\nThis option is fundamentally flawed and dangerous.\n-   It incorrectly dismisses the importance of regular uterine contractions. Placing a cerclage during active preterm labor is a major contraindication. While tocolysis is a therapy for preterm labor, it is not always effective, and cerclage is not a treatment for labor.\n-   It wrongly dismisses CRP. While non-specific, ignoring a valuable, rapid inflammatory marker is poor clinical practice and increases the risk of placing a stitch in an infected environment.\n-   Relying on \"initial vaginal culture\" is vague and impractical. A Gram stain is not definitive, and waiting for final results introduces an unacceptable delay.\n**Verdict: Incorrect.**\n\n**C. Require a negative vaginal culture before cerclage to exclude infection. While awaiting the final culture result over $48$ to $72$ hours, observe the patient; if the cervix dilates further, start tocolysis and proceed with cerclage even if maternal temperature is $\\geq 38.0\\,^{\\circ}\\mathrm{C}$ and CRP is elevated, because the benefits of mechanical support outweigh the risks.**\n\nThis option describes a sequence of actions that constitutes medical malpractice.\n-   The mandatory $48$ to $72$-hour waiting period for culture results is unacceptable in an emergent setting and would likely result in the loss of opportunity for cerclage placement.\n-   The recommendation to proceed with cerclage in the presence of fever (temperature $\\geq 38.0\\,^{\\circ}\\mathrm{C}$) and elevated CRP is a direct violation of a fundamental safety principle. This would be tantamount to knowingly placing a foreign body into an actively infected site, risking severe maternal and fetal sepsis. The claim that mechanical benefit outweighs this risk is false.\n**Verdict: Incorrect.**\n\n**D. Use a low-threshold inflammatory trigger: if either maternal temperature $\\geq 37.5\\,^{\\circ}\\mathrm{C}$ or CRP $\\geq 5\\,\\mathrm{mg/L}$, classify as infection-driven dilation and defer cerclage; if both are below these thresholds, proceed with cerclage regardless of the presence of regular uterine contractions, because contractions in the second trimester are often physiological and do not contraindicate cerclage.**\n\nThis option is flawed in its thresholds and its logic.\n-   The temperature threshold of $\\geq 37.5\\,^{\\circ}\\mathrm{C}$ is overly sensitive and does not meet the clinical definition of fever. The CRP threshold of $\\geq 5\\,\\mathrm{mg/L}$ is also very low and could be considered within the normal range in some assays. These low thresholds would lead to withholding cerclage from many appropriate candidates.\n-   Most critically, it explicitly states to proceed \"regardless of the presence of regular uterine contractions.\" This is profoundly incorrect. It confuses physiological, irregular Braxton-Hicks contractions with the \"regular uterine activity\" that defines preterm labor. Preterm labor is an absolute contraindication to cerclage.\n**Verdict: Incorrect.**\n\nBased on the analysis, Option A is the only algorithm that is safe, effective, timely, and consistent with established principles of obstetric care.", "answer": "$$\\boxed{A}$$", "id": "4411079"}, {"introduction": "After identifying a suitable candidate for cerclage, it's vital to quantify the intervention's expected impact. This practice focuses on the fundamental biostatistical tools used to interpret evidence from clinical trials: Absolute Risk Reduction ($ARR$) and Number Needed to Treat ($NNT$). By working through this problem [@problem_id:4411063], you will translate raw outcome probabilities into clinically intuitive metrics that are essential for evidence-based practice and patient counseling.", "problem": "A high-risk obstetric cohort with a history consistent with cervical insufficiency is enrolled in a prospective study evaluating transvaginal cerclage. The primary endpoint is preterm birth before $34$ weeks. In the expectant management group, the observed probability of preterm birth before $34$ weeks is $0.40$. In the cerclage group, the observed probability of preterm birth before $34$ weeks is $0.25$. Assume a homogeneous treatment effect across individuals and independence of outcomes across patients.\n\nUsing only fundamental definitions of probability of an event and treatment effect in risk terms, compute the expected absolute risk reduction (ARR) for preterm birth before $34$ weeks attributable to cerclage relative to expectant management, and the corresponding number needed to treat (NNT) with cerclage to prevent one preterm birth before $34$ weeks.\n\nExpress the absolute risk reduction as a decimal rounded to four significant figures. Express the number needed to treat as an exact fraction in simplest terms. Do not append units or percentage signs to your answers.", "solution": "The problem statement is evaluated for validity before proceeding to a solution.\n\n### Step 1: Extract Givens\n-   Primary endpoint: Preterm birth before $34$ weeks.\n-   Probability of the endpoint in the expectant management group: $0.40$.\n-   Probability of the endpoint in the cerclage group: $0.25$.\n-   Assumption: Homogeneous treatment effect across individuals.\n-   Assumption: Independence of outcomes across patients.\n-   Task 1: Compute the expected absolute risk reduction (ARR).\n-   Task 2: Compute the number needed to treat (NNT).\n-   Formatting Requirement 1: Express ARR as a decimal rounded to four significant figures.\n-   Formatting Requirement 2: Express NNT as an exact fraction in simplest terms.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed based on the specified criteria.\n\n-   **Scientifically Grounded**: The problem is grounded in the principles of clinical epidemiology and biostatistics. The concepts of absolute risk reduction (ARR) and number needed to treat (NNT) are standard metrics used to quantify the effect of an intervention. The scenario described—comparing cerclage to expectant management for preventing preterm birth in a high-risk population—is a classic and clinically relevant topic in obstetrics. The provided probabilities ($0.40$ and $0.25$) are plausible for such a cohort.\n-   **Well-Posed**: The problem is well-posed. It provides all necessary data and defines a clear objective: to calculate two specific, well-defined quantities (ARR and NNT). The assumptions of a homogeneous treatment effect and independence of outcomes are standard simplifying assumptions that ensure a unique and meaningful solution exists.\n-   **Objective**: The problem is stated in objective, quantitative language, free from bias or subjective claims.\n\nThe problem statement does not exhibit any of the listed flaws (Scientific Unsoundness, Non-Formalizable, Incomplete Setup, Unrealistic, Ill-Posed, Pseudo-Profound, or Outside Scientific Verifiability). It is a standard, formalizable problem in applied probability and biostatistics.\n\n### Step 3: Verdict and Action\nThe problem statement is valid. A solution will be provided.\n\n### Solution Derivation\n\nLet $E$ denote the event of preterm birth before $34$ weeks.\nLet $P_E$ be the probability of event $E$ in the expectant management (control) group. This is also known as the control event rate (CER).\nLet $P_C$ be the probability of event $E$ in the cerclage (treatment) group. This is also known as the experimental event rate (EER).\n\nFrom the problem statement, we are given:\n$$ P_E = \\text{CER} = 0.40 $$\n$$ P_C = \\text{EER} = 0.25 $$\n\nThe absolute risk reduction (ARR) is defined as the difference in the event rates between the control group and the treatment group. It quantifies the absolute decrease in risk attributable to the intervention. The formula is:\n$$ \\text{ARR} = \\text{CER} - \\text{EER} $$\n\nSubstituting the given values:\n$$ \\text{ARR} = P_E - P_C = 0.40 - 0.25 = 0.15 $$\n\nThe problem requires the ARR to be expressed as a decimal rounded to four significant figures. The value $0.15$ has two significant figures. To express it with four, we append two zeros.\n$$ \\text{ARR} = 0.1500 $$\n\nThe number needed to treat (NNT) is the reciprocal of the absolute risk reduction. It represents the average number of patients who must be treated with the intervention to prevent one additional adverse event (in this case, one preterm birth before $34$ weeks). The validity of the NNT as a summary measure rests on the assumption of a homogeneous treatment effect, which is explicitly stated in the problem. The formula for NNT is:\n$$ \\text{NNT} = \\frac{1}{\\text{ARR}} $$\n\nUsing the calculated value of ARR:\n$$ \\text{NNT} = \\frac{1}{0.15} $$\n\nThe problem requires the NNT to be expressed as an exact fraction in simplest terms. We convert the decimal to a fraction:\n$$ 0.15 = \\frac{15}{100} $$\nTherefore:\n$$ \\text{NNT} = \\frac{1}{\\frac{15}{100}} = \\frac{100}{15} $$\n\nTo simplify the fraction, we find the greatest common divisor of the numerator and the denominator. Both $100$ and $15$ are divisible by $5$.\n$$ \\frac{100 \\div 5}{15 \\div 5} = \\frac{20}{3} $$\nThis fraction is in its simplest form as $20$ and $3$ are coprime.\n\nThe computed values are an ARR of $0.1500$ and an NNT of $\\frac{20}{3}$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.1500  \\frac{20}{3}\n\\end{pmatrix}\n}\n$$", "id": "4411063"}, {"introduction": "Sophisticated clinical judgment involves weighing the potential benefits of an intervention against its inherent risks. This problem moves beyond simple efficacy to a more comprehensive decision analysis by introducing the Number Needed to Harm ($NNH$) and the concept of net clinical benefit. This exercise [@problem_id:4411029] will challenge you to integrate both positive and negative outcomes into a single framework, reflecting the complex trade-offs encountered daily in clinical practice.", "problem": "A patient population with a history consistent with cervical insufficiency is being considered for transvaginal cervical cerclage. For decision analysis, model each clinical outcome as a Bernoulli event with a constant probability over the cohort, and assume independence between benefit and harm events at the level of expected counts. Use the following empirically plausible risks: the baseline probability of clinical chorioamnionitis without cerclage is $0.02$, and the probability with cerclage is $0.05$. The baseline probability of delivery before $34$ weeks without cerclage is $0.30$, and the probability with cerclage is $0.18$. Define the Number Needed to Harm (NNH) and the Number Needed to Treat (NNT) using the core interpretation of reciprocal count metrics derived from risk differences. For a composite decision metric, define net clinical benefit per treated patient as the expected benefit minus a weighted expected harm, where benefit is one preterm birth prevented (weight $w_{b} = 1$) and harm is one chorioamnionitis event caused (weight $w_{h} = 0.25$), reflecting that a chorioamnionitis event is assessed to be one-quarter as clinically significant as a preterm birth prevented in this context. \n\nCompute the NNH for chorioamnionitis and then calculate the net clinical benefit when $100$ patients receive cerclage compared with no cerclage, using the above weights. Report only the net clinical benefit as your final numeric answer. Round your final answer to four significant figures. Express the net clinical benefit in the unit \"patients per $100$ treated.\"", "solution": "The problem requires the calculation of two metrics related to a clinical decision analysis for cervical cerclage: the Number Needed to Harm (NNH) for chorioamnionitis and the net clinical benefit for a cohort of $100$ treated patients. The final answer should be the net clinical benefit, rounded to four significant figures.\n\nFirst, let's formalize the given information. Let $C$ denote the event of receiving a cerclage (treatment) and $\\neg C$ denote the event of not receiving a cerclage (control). Let $H$ be the harm event, defined as clinical chorioamnionitis. Let $B$ be the adverse outcome event, defined as delivery before $34$ weeks. The reduction of this event is the benefit.\n\nThe probabilities provided are:\n- Probability of harm in the control group: $P(H|\\neg C) = 0.02$\n- Probability of harm in the treatment group: $P(H|C) = 0.05$\n- Probability of the adverse outcome in the control group: $P(B|\\neg C) = 0.30$\n- Probability of the adverse outcome in the treatment group: $P(B|C) = 0.18$\n\nThe problem asks to first compute the NNH for chorioamnionitis. The NNH is the reciprocal of the Absolute Risk Increase (ARI). The ARI for the harm event $H$ is the difference in the probability of harm between the treatment and control groups.\n$$\nARI_H = P(H|C) - P(H|\\neg C) = 0.05 - 0.02 = 0.03\n$$\nThe Number Needed to Harm is then:\n$$\nNNH = \\frac{1}{ARI_H} = \\frac{1}{0.03} = \\frac{100}{3} \\approx 33.33\n$$\nThis means that for every $33$ patients treated with cerclage, one additional case of chorioamnionitis is expected to occur that would not have occurred otherwise.\n\nNext, we address the net clinical benefit. This requires calculating the expected benefit (preterm births prevented) and the expected harm (chorioamnionitis caused) when a cohort of $N=100$ patients is treated.\n\nThe benefit is the prevention of preterm delivery. We first calculate the Absolute Risk Reduction (ARR) for this outcome. The ARR is the difference in the probability of the adverse outcome between the control and treatment groups.\n$$\nARR_B = P(B|\\neg C) - P(B|C) = 0.30 - 0.18 = 0.12\n$$\nThis ARR of $0.12$ represents the probability that a single patient will benefit from the treatment by avoiding a preterm birth.\n\nFor a cohort of $N=100$ patients, we can calculate the total number of expected benefits and harms.\nThe expected number of preterm births prevented, $N_{\\text{benefit}}$, is:\n$$\nN_{\\text{benefit}} = N \\times ARR_B = 100 \\times 0.12 = 12\n$$\nSo, treating $100$ patients is expected to prevent $12$ preterm births.\n\nThe expected number of chorioamnionitis cases caused, $N_{\\text{harm}}$, is:\n$$\nN_{\\text{harm}} = N \\times ARI_H = 100 \\times 0.03 = 3\n$$\nSo, treating $100$ patients is expected to cause $3$ additional cases of chorioamnionitis.\n\nThe problem defines a composite decision metric, the net clinical benefit ($NCB$), which incorporates clinical judgment about the relative severity of the benefit versus the harm. The weights are given as $w_b=1$ for the benefit (one preterm birth prevented) and $w_h=0.25$ for the harm (one chorioamnionitis event caused).\n\nThe net clinical benefit for the cohort of $100$ patients, $NCB_{100}$, is calculated as:\n$$\nNCB_{100} = (w_b \\times N_{\\text{benefit}}) - (w_h \\times N_{\\text{harm}})\n$$\nSubstituting the calculated values and given weights:\n$$\nNCB_{100} = (1 \\times 12) - (0.25 \\times 3)\n$$\n$$\nNCB_{100} = 12 - 0.75\n$$\n$$\nNCB_{100} = 11.25\n$$\nThe result, $11.25$, represents the net positive outcome in units of \"benefit-equivalents\" for every $100$ patients treated. The problem asks for this value to be rounded to four significant figures. The number $11.25$ already has exactly four significant figures ($1$, $1$, $2$, $5$), so no rounding is necessary.", "answer": "$$\\boxed{11.25}$$", "id": "4411029"}]}